CS251799B2 - Method of bacampiciline hydrochloride stabilization - Google Patents
Method of bacampiciline hydrochloride stabilization Download PDFInfo
- Publication number
- CS251799B2 CS251799B2 CS858022A CS802285A CS251799B2 CS 251799 B2 CS251799 B2 CS 251799B2 CS 858022 A CS858022 A CS 858022A CS 802285 A CS802285 A CS 802285A CS 251799 B2 CS251799 B2 CS 251799B2
- Authority
- CS
- Czechoslovakia
- Prior art keywords
- acid
- hydrochloride
- compounds
- penicilová
- ethyl acetate
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 22
- 230000006641 stabilisation Effects 0.000 title claims abstract 3
- 238000011105 stabilization Methods 0.000 title claims abstract 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 title claims description 28
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 60
- 150000001875 compounds Chemical class 0.000 claims description 41
- 239000002253 acid Substances 0.000 claims description 37
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims description 26
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 claims description 17
- 229960000541 cetyl alcohol Drugs 0.000 claims description 17
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims description 17
- XUPYJHCZDLZNFP-UHFFFAOYSA-N butyl butanoate Chemical compound CCCCOC(=O)CCC XUPYJHCZDLZNFP-UHFFFAOYSA-N 0.000 claims description 4
- 239000003381 stabilizer Substances 0.000 claims description 3
- 235000021355 Stearic acid Nutrition 0.000 claims description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 2
- 239000008117 stearic acid Substances 0.000 claims description 2
- IWVTXAGTHUECPN-ANBBSHPLSA-N bacampicillin hydrochloride Chemical compound [H+].[Cl-].C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)[C@H](C(S3)(C)C)C(=O)OC(C)OC(=O)OCC)=CC=CC=C1 IWVTXAGTHUECPN-ANBBSHPLSA-N 0.000 abstract description 14
- 229960005412 bacampicillin hydrochloride Drugs 0.000 abstract description 13
- 150000001298 alcohols Chemical class 0.000 abstract description 3
- 230000015556 catabolic process Effects 0.000 abstract description 3
- 238000006731 degradation reaction Methods 0.000 abstract description 3
- 150000002148 esters Chemical class 0.000 abstract description 3
- 238000005469 granulation Methods 0.000 abstract description 3
- 230000003179 granulation Effects 0.000 abstract description 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 3
- 150000001335 aliphatic alkanes Chemical class 0.000 abstract description 2
- 150000001336 alkenes Chemical class 0.000 abstract description 2
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 2
- 229930195729 fatty acid Natural products 0.000 abstract 2
- 239000000194 fatty acid Substances 0.000 abstract 2
- 150000004665 fatty acids Chemical class 0.000 abstract 2
- 238000010348 incorporation Methods 0.000 abstract 1
- 239000000126 substance Substances 0.000 description 15
- 239000008187 granular material Substances 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 239000002904 solvent Substances 0.000 description 9
- 230000001681 protective effect Effects 0.000 description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000013078 crystal Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- YLYBTZIQSIBWLI-UHFFFAOYSA-N octyl acetate Chemical compound CCCCCCCCOC(C)=O YLYBTZIQSIBWLI-UHFFFAOYSA-N 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000000087 stabilizing effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- -1 1-ethoxycarbonyloxyethyl Chemical group 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- SNRUBQQJIBEYMU-UHFFFAOYSA-N dodecane Chemical compound CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 3
- RZJRJXONCZWCBN-UHFFFAOYSA-N octadecane Chemical compound CCCCCCCCCCCCCCCCCC RZJRJXONCZWCBN-UHFFFAOYSA-N 0.000 description 3
- 150000002894 organic compounds Chemical class 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 238000001238 wet grinding Methods 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- OIZXRZCQJDXPFO-UHFFFAOYSA-N Octadecyl acetate Chemical compound CCCCCCCCCCCCCCCCCCOC(C)=O OIZXRZCQJDXPFO-UHFFFAOYSA-N 0.000 description 2
- PWLNAUNEAKQYLH-UHFFFAOYSA-N Octyl butanoate Chemical compound CCCCCCCCOC(=O)CCC PWLNAUNEAKQYLH-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000002075 anti-alcohol Effects 0.000 description 2
- 108700023668 bacilysin Proteins 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 239000000428 dust Substances 0.000 description 2
- SHZIWNPUGXLXDT-UHFFFAOYSA-N ethyl hexanoate Chemical compound CCCCCC(=O)OCC SHZIWNPUGXLXDT-UHFFFAOYSA-N 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000003801 milling Methods 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- WNPVZANXRCPJPW-UHFFFAOYSA-N 5-[isocyano-(4-methylphenyl)sulfonylmethyl]-1,2,3-trimethoxybenzene Chemical compound COC1=C(OC)C(OC)=CC(C([N+]#[C-])S(=O)(=O)C=2C=CC(C)=CC=2)=C1 WNPVZANXRCPJPW-UHFFFAOYSA-N 0.000 description 1
- VQMPJLWTJNPKFW-UHFFFAOYSA-N 5-butylicosan-5-ol Chemical compound CCCCCCCCCCCCCCCC(O)(CCCC)CCCC VQMPJLWTJNPKFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 235000021360 Myristic acid Nutrition 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- 241000283220 Odobenus rosmarus Species 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 150000007933 aliphatic carboxylic acids Chemical class 0.000 description 1
- DCAYPVUWAIABOU-UHFFFAOYSA-N alpha-n-hexadecene Natural products CCCCCCCCCCCCCCCC DCAYPVUWAIABOU-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229960002699 bacampicillin Drugs 0.000 description 1
- PFOLLRNADZZWEX-FFGRCDKISA-N bacampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)[C@H](C(S3)(C)C)C(=O)OC(C)OC(=O)OCC)=CC=CC=C1 PFOLLRNADZZWEX-FFGRCDKISA-N 0.000 description 1
- 229940088623 biologically active substance Drugs 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 238000004455 differential thermal analysis Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000009837 dry grinding Methods 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 1
- 229940011051 isopropyl acetate Drugs 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 229940043348 myristyl alcohol Drugs 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 229940038384 octadecane Drugs 0.000 description 1
- YCOFRPYSZKIPBQ-UHFFFAOYSA-N penicillic acid Natural products COC1=CC(=O)OC1(O)C(C)=C YCOFRPYSZKIPBQ-UHFFFAOYSA-N 0.000 description 1
- VOUGEZYPVGAPBB-UHFFFAOYSA-N penicillin acid Natural products OC(=O)C=C(OC)C(=O)C(C)=C VOUGEZYPVGAPBB-UHFFFAOYSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 238000000634 powder X-ray diffraction Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- NIJJYAXOARWZEE-UHFFFAOYSA-M valproate Chemical compound CCCC(C([O-])=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-M 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D499/04—Preparation
- C07D499/14—Preparation of salts
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE8405611A SE8405611D0 (sv) | 1984-11-09 | 1984-11-09 | Process for stabilization of bacampicillin hydrochloride |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CS251799B2 true CS251799B2 (en) | 1987-08-13 |
Family
ID=20357678
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CS858022A CS251799B2 (en) | 1984-11-09 | 1985-11-07 | Method of bacampiciline hydrochloride stabilization |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US4626532A (en]) |
| EP (1) | EP0187626A1 (en]) |
| JP (1) | JPS61115031A (en]) |
| KR (1) | KR860004065A (en]) |
| CN (1) | CN85108260A (en]) |
| AU (1) | AU581694B2 (en]) |
| CS (1) | CS251799B2 (en]) |
| DD (1) | DD239206A5 (en]) |
| DK (1) | DK509085A (en]) |
| EG (1) | EG17292A (en]) |
| ES (1) | ES8704176A1 (en]) |
| FI (1) | FI854340A7 (en]) |
| GB (1) | GB2167067B (en]) |
| GR (1) | GR852706B (en]) |
| HU (1) | HUT40135A (en]) |
| IL (1) | IL76727A (en]) |
| NZ (1) | NZ214096A (en]) |
| PH (1) | PH21760A (en]) |
| PL (1) | PL256116A1 (en]) |
| PT (1) | PT81455B (en]) |
| SE (1) | SE8405611D0 (en]) |
| YU (1) | YU167085A (en]) |
| ZA (1) | ZA858043B (en]) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3531648B2 (ja) * | 1998-08-04 | 2004-05-31 | 武田シェリング・プラウ アニマルヘルス株式会社 | β−ラクタム抗生物質の安定化製剤 |
| US20030180249A1 (en) * | 2002-03-18 | 2003-09-25 | Khanna Satish Chandra | Dosage forms for hygroscopic active ingredients |
| US8986781B2 (en) * | 2005-10-27 | 2015-03-24 | Corning Incorporated | Immobilized multi-layer artificial membrane for permeability measurements (PAMPA) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1293590A (en) * | 1969-11-11 | 1972-10-18 | Leo Pharm Prod Ltd | New penicillanic acid derivatives |
| US3873521A (en) * | 1970-09-17 | 1975-03-25 | Astra Laekemedel Ab | Esters of {60 -amino penicillins |
| JPS56140915A (en) * | 1980-04-07 | 1981-11-04 | Yamanouchi Pharmaceut Co Ltd | Pharmaceutical preparation for solid drug |
| US4321253A (en) * | 1980-08-22 | 1982-03-23 | Beatty Morgan L | Suspension of microencapsulated bacampicillin acid addition salt for oral, especially pediatric, administration |
| IE51846B1 (en) * | 1980-11-17 | 1987-04-15 | Leo Pharm Prod Ltd | Pharmaceutical preparation for veterinary use and an appliance containing it |
| SE8103843L (sv) * | 1981-06-18 | 1982-12-19 | Astra Laekemedel Ab | Farmaceutisk mixtur |
| SE8203953D0 (sv) * | 1982-06-24 | 1982-06-24 | Astra Laekemedel Ab | Pharmaceutical mixture |
-
1984
- 1984-11-09 SE SE8405611A patent/SE8405611D0/xx unknown
-
1985
- 1985-10-16 IL IL76727A patent/IL76727A/xx unknown
- 1985-10-18 ZA ZA858043A patent/ZA858043B/xx unknown
- 1985-10-21 YU YU01670/85A patent/YU167085A/xx unknown
- 1985-10-29 US US06/792,507 patent/US4626532A/en not_active Expired - Fee Related
- 1985-10-31 EP EP85850351A patent/EP0187626A1/en not_active Withdrawn
- 1985-11-05 DK DK509085A patent/DK509085A/da not_active Application Discontinuation
- 1985-11-05 FI FI854340A patent/FI854340A7/fi not_active Application Discontinuation
- 1985-11-06 NZ NZ214096A patent/NZ214096A/xx unknown
- 1985-11-06 HU HU854267A patent/HUT40135A/hu unknown
- 1985-11-06 PL PL25611685A patent/PL256116A1/xx unknown
- 1985-11-06 AU AU49382/85A patent/AU581694B2/en not_active Ceased
- 1985-11-07 EG EG715/85A patent/EG17292A/xx active
- 1985-11-07 CS CS858022A patent/CS251799B2/cs unknown
- 1985-11-08 ES ES548698A patent/ES8704176A1/es not_active Expired
- 1985-11-08 JP JP60249149A patent/JPS61115031A/ja active Pending
- 1985-11-08 GR GR852706A patent/GR852706B/el unknown
- 1985-11-08 GB GB08527612A patent/GB2167067B/en not_active Expired
- 1985-11-08 DD DD85282660A patent/DD239206A5/de unknown
- 1985-11-08 PH PH33042A patent/PH21760A/en unknown
- 1985-11-08 PT PT81455A patent/PT81455B/pt unknown
- 1985-11-08 KR KR1019850008331A patent/KR860004065A/ko not_active Withdrawn
- 1985-11-09 CN CN198585108260A patent/CN85108260A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR860004065A (ko) | 1986-06-16 |
| YU167085A (en) | 1988-12-31 |
| IL76727A (en) | 1989-09-10 |
| GB8527612D0 (en) | 1985-12-11 |
| ES8704176A1 (es) | 1987-03-16 |
| EG17292A (en) | 1990-08-30 |
| PT81455A (en) | 1985-12-01 |
| PH21760A (en) | 1988-02-18 |
| ZA858043B (en) | 1987-04-29 |
| FI854340A0 (fi) | 1985-11-05 |
| PL256116A1 (en) | 1988-05-12 |
| FI854340L (fi) | 1986-05-10 |
| GB2167067B (en) | 1988-06-22 |
| CN85108260A (zh) | 1986-04-10 |
| DK509085D0 (da) | 1985-11-05 |
| EP0187626A1 (en) | 1986-07-16 |
| HUT40135A (en) | 1986-11-28 |
| GR852706B (en]) | 1986-03-10 |
| IL76727A0 (en) | 1986-02-28 |
| DK509085A (da) | 1986-05-10 |
| NZ214096A (en) | 1988-09-29 |
| US4626532A (en) | 1986-12-02 |
| AU581694B2 (en) | 1989-03-02 |
| GB2167067A (en) | 1986-05-21 |
| FI854340A7 (fi) | 1986-05-10 |
| PT81455B (en) | 1987-09-17 |
| JPS61115031A (ja) | 1986-06-02 |
| AU4938285A (en) | 1986-05-15 |
| ES548698A0 (es) | 1987-03-16 |
| DD239206A5 (de) | 1986-09-17 |
| SE8405611D0 (sv) | 1984-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR0183027B1 (ko) | 류코트리엔의 작용에 대한 길항작용이 요구되는 질환의 치료용 약학 조성물 및 이의 제조 방법 | |
| US4404183A (en) | Sustained release pharmaceutical composition of solid medical material | |
| JP4608031B2 (ja) | アミノ酸／シクロデキストリン混合物による酸感受性ベンズイミダゾール類の安定化 | |
| RU2103995C1 (ru) | Микрогранулы омепразола и способ их получения | |
| KR850000625B1 (ko) | 판크레아틴 환제의 제조방법 | |
| CA2008972C (en) | Nifedipine-containing pharmaceutical compositions and process for the preparation thereof | |
| US4138475A (en) | Sustained release pharmaceutical composition | |
| CA1147650A (en) | Sustained release pharmaceutical compositions | |
| EP1575563B1 (en) | Non-hygroscopic formulation comprising a hydroscopic drug | |
| KR20120089461A (ko) | 향상된 안정성을 갖는 (ｚ)-2-시아노-3-하이드록시-부트-2-엔산-(4''-트리플루오로메틸페닐)-아미드 정제 제형 | |
| FR2550092A1 (fr) | Preparation medicamenteuse solide a deux phases et son procede d'obtention | |
| US5424301A (en) | Starch stabilized o-substituted tetrahydropyridine oxime cholinergic agents | |
| US4897267A (en) | Microparticles comprising a biodegradable polymer controlling the release of an antimalaria active principle, pharmaceutical compositions comprising it and process for its preparation | |
| KR0148006B1 (ko) | 용해속도를 증가시키기에 적합한 형태로 중합체 기재로 지지된 저가용성약제 및 이의 제조방법 | |
| CS251799B2 (en) | Method of bacampiciline hydrochloride stabilization | |
| CN1282247A (zh) | 稳定化药用组合物 | |
| JP3456211B2 (ja) | 持続性製剤 | |
| JPH0222225A (ja) | 胃酸分泌抑制剤含有固型製剤 | |
| KR950015059B1 (ko) | 오메프라졸의 신규 경구용 약제 | |
| DE69728043T2 (de) | Thermisch immobilisierte polysaccharidderivate | |
| WO2002005746A2 (en) | The process of manufacturing pharmaceutical grade tannates | |
| KR101172539B1 (ko) | 발데나필 하이드로클로라이드 삼수화물을 포함하는 약물 | |
| KR0147461B1 (ko) | 경구용 오메프라졸 제제 | |
| EP0667153A1 (en) | Method of manufacturing composition for solid medicine | |
| WO2005023225A1 (en) | Cilostazol adsorbate |